Product menu

Woman with shingles rash

THIS IS SHINGLES. SHINGLES PAIN CAN BE SEVERE, DISABLING AND LAST FOR WEEKS.1

SHINGRIX pack shot

What is SHINGRIX?

SHINGRIX is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or old and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.1

See Product Monograph

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

View reconstitution instructions for SHINGRIX

You and your office staff can learn how to administer SHINGRIX step by step.

View additional SHINGRIX videos

Important product information

Product Monograph

download

Important safety information

Access

Resources for you and your patients

Access
Checkmark icon

SHINGRIX: Recommendations from NACI and CIQ

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI) and the Comité sur l’immunisation du Québec (CIQ).2,3

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.4

Learn more

Important safety information

Indications and clinical use:

  • SHINGRIX is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Contraindications:

  • Individuals with a known hypersensitivity to the active substance or to any component of the vaccine

Most serious warnings and precautions:

  • Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously

Other relevant warnings and precautions:

  • A protective immune response may not be elicited in all vaccinees
  • Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
  • Postpone in those with acute severe febrile illness
  • Use with caution in those with thrombocytopenia or any coagulation disorder
  • Syncope following or before any vaccination as a psychogenic response
  • Fever and shivering were more frequent when the 23-valent pneumococcal polysaccharide (PPV23) vaccine was co-administered with SHINGRIX
  • Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
  • Increased risk of Guillain-Barré syndrome was observed in a post-marketing observational study in individuals 65 years of age or older within 42 days following vaccination (estimated 3 excess cases per million doses administered), with insufficient information available to determine a causal relationship with SHINGRIX

For more information:

Please consult the Product Monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions and drug interactions which have not been discussed in this piece. To request a Product Monograph, or to report an adverse event, please call 1-800-387-7374.

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  3. Reproduction of information from the PIQ, 7th ed. Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/. Accessed November 30, 2022.
    The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.
  4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23